title: Cetuximab-induced esophageal ulcer: the first report in literature.
authors.affiliation: Department of Oncology, School of Medicine, Hacettepe University, Ankara, Turkey.
authors.forename: Taner
authors.initials: T
authors.lastname: Babacan
authors.affiliation: Department of Internal Medicine, School of Medicine, Adiyaman University, Adiyaman, Turkey. turkbeyler@mynet.com.
authors.forename: Ibrahim Halil
authors.initials: IH
authors.lastname: Turkbeyler
authors.affiliation: Department of Gastroenterology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
authors.forename: Muhammet Sait
authors.initials: MS
authors.lastname: Dag
authors.affiliation: Department of Internal Medicine, School of Medicine, Gaziantep University, Gaziantep, Turkey.
authors.forename: Ismail
authors.initials: I
authors.lastname: Dilli
authors.affiliation: Department of Internal Medicine, School of Medicine, Gaziantep University, Gaziantep, Turkey.
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.affiliation: Department of Oncology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000006:Abdomen, Acute / Q000209:etiology; D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis* / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D059248:Chemoradiotherapy; D003125:Colostomy; D004941:Esophagitis / Q000139:chemically induced* / Q000378:metabolism / Q000628:therapy; D004945:Esophagoscopy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000601:surgery*; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000009:adverse effects* / Q000379:methods; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011351:Proctoscopy; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D012004:Rectal Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014456:Ulcer / Q000139:chemically induced* / Q000378:metabolism / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000378:metabolism; D014839:Vomiting / Q000209:etiology; D018631:ras Proteins / Q000187:drug effects / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C117307:KRAS protein, human; D009944:Organoplatinum Compounds; D011518:Proto-Oncogene Proteins; D042461:Vascular Endothelial Growth Factor A; D000077150:Oxaliplatin; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D005472:Fluorouracil; D002166:Camptothecin